A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
This study is investigating a new treatment called NGN-401 for females with typical Rett Syndrome. NGN-401 is a type of gene therapy designed to help the body make a vital protein, MeCP2, which is often missing or not working correctly in people with Rett Syndrome. The main goals are to find out how effective and safe this new treatment is. The treatment is given as a single dose directly into the fluid around the brain under general anaesthesia. Participants will be carefully monitored for three years after receiving the treatment, and then will have the option to take part in a longer follow-up study for twelve years to keep track of their health and the treatment's effects. This study aims to potentially improve the lives of those living with Rett Syndrome.
במבט חטוף
על מה המחקר הזה?
Rett Syndrome is a complex genetic condition that mainly affects girls, leading to problems with communication, movement, and other body functions. It's caused by a change (mutation) in a gene called MECP2. This gene is responsible for making a protein, also called MeCP2, which is crucial for healthy brain development and function. When this protein isn't working properly, it can cause the wide range of symptoms seen in Rett Syndrome.
This new study is looking at a treatment called NGN-401, which is a type of 'gene therapy'. Think of gene therapy like sending a working copy of a faulty gene into the body. In this case, NGN-401 aims to deliver a healthy, full-length MECP2 gene into the cells. The clever part is that it's designed to make just the right amount of the MeCP2 protein – enough to help, but not too much, as too much can also cause problems.
The hope is that by providing this working gene, the body can start producing the missing or faulty MeCP2 protein correctly, which could potentially improve some of the symptoms of Rett Syndrome. This study is an important step in understanding if NGN-401 can safely and effectively make a positive difference in the lives of girls and women with this condition.
נקודות עיקריות
- This study is testing a new gene therapy (NGN-401) for Rett Syndrome.
- It aims to replace a missing or faulty protein (MeCP2) in the brain.
- The treatment is a single dose, given under general anaesthesia.
- Participants will have careful follow-up for at least three years.
- This study is for females with typical Rett Syndrome, aged 3 years and over.
- It's important to discuss all aspects with your doctor before considering participation.
מי עשוי להיות זכאי?
This study is looking for females with a confirmed diagnosis of typical Rett Syndrome. To be considered, you must have a specific change in the MECP2 gene that causes the condition. For this main part of the study, participants should be at least three years old, but there isn't an upper age limit mentioned. Your current medication for seizures should have been stable for at least 12 weeks, and you should be past the initial 'regression' stage of Rett Syndrome.
There are also some practical requirements. For instance, you and your caregiver should live close enough to the study centre – within a two-hour drive – for at least three months after the treatment.
Certain conditions might mean someone can't take part. For example, if you have very good hand function, or another significant health problem that isn't Rett Syndrome. Also, if you've previously taken a treatment called trofinetide, you might still be able to join, but you can't be taking it when you start the study. The study team will review all your medical information carefully to see if this study is suitable for you.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Are you female with a diagnosis of typical Rett Syndrome?
- Is your Rett Syndrome caused by a known MECP2 gene change?
- Are you at least 3 years old?
- Are you past the 'regression' stage of Rett Syndrome?
- Can you live within a 2-hour drive of the study centre for at least 3 months after potential treatment?
- Have you never taken trofinetide, or stopped taking it for a given reason?
מה כרוך בהשתתפות?
If you decide to take part in this study, the main treatment involves a single dose of NGN-401. This treatment is given directly into the fluid surrounding the brain (called intracerebroventricular delivery). This procedure is done while you are under general anaesthesia, meaning you will be asleep and won't feel anything during the administration.
After receiving the treatment, you will be carefully monitored for your health and the treatment's effects over three years. This will involve regular visits to the study centre for check-ups, assessments, and to make sure everything is going well. These visits are important for the doctors to understand how the treatment is working and to keep you safe. Following this three-year period, you will have the option to join a longer follow-up study that will last for 12 years. This extended follow-up helps researchers understand the long-term effects of the gene therapy.
סיכונים ותועלות פוטנציאליים
Locations (16)
- אוניברסיטת אלבמה בבירמינגהםמיקוד מאומתבירמינגהם, ארצות הברית
- בית החולים לילדים UCSF בניוף אוקלנדמיקוד מאומתאוקלנד, ארצות הברית
- בית החולים לילדים קולורדומיקוד מאומתאורורה, ארצות הברית
- Nicklaus Children's Hospital Research Instituteמיקוד מאומתמיאמי, ארצות הברית
- Rush University Medical Centerמיקוד מאומתשיקגו, ארצות הברית
- Kennedy Krieger Instituteמיקוד מאומתבולטימור, ארצות הברית
- Boston Children's Hospitalמיקוד מאומתבוסטון, ארצות הברית
- מרכז רפואי מונטיפיורימיקוד מאומתניו יורק, ארצות הברית
- UNC at Chapel Hillמיקוד מאומתצ'אפל היל, ארצות הברית
- בית החולים לילדים ניישנווידמיקוד מאומתקולומבוס, ארצות הברית
- בית החולים לילדים של פילדלפיהמיקוד מאומתפילדלפיה, ארצות הברית
- Vanderbilt University Medical Centerמיקוד מאומתנאשוויל, ארצות הברית
שאלות נפוצות
What is gene therapy?
Gene therapy aims to fix health problems caused by faulty genes. It involves introducing a working copy of a gene into the body to help it function properly.
How is NGN-401 given?
NGN-401 is given as a single dose directly into the fluid around the brain, while the patient is asleep under general anaesthesia.
How long will the study participation last?
Participants will be followed for three years after treatment, with an option to join a long-term follow-up study for an additional 12 years.
Can boys with Rett Syndrome participate?
No, this specific study is only for females with Rett Syndrome.
Will I have to stop other medications for Rett Syndrome?
If you are taking anti-epileptic drugs, your dosage needs to have been stable for at least 12 weeks. If you've taken trofinetide, you cannot be currently taking it when you start the study.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.